Begge aktive stoffer har været på markedet i EU siden begyndelsen af 2000- tallet: emtricitabin fik markedsføringstilladelse under navnet Emtriva i 2003, og tenofovirdisoproxil fik markedsføringstilla - delse under navnet Viread i 2002.
Both active substances have been available in the European Union (EU) since the early 2000s: emtricitabine was granted marketing approval as Emtriva in 2003, and tenofovir disoproxil was granted marketing approval as Viread in 2002.